Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud and unlawful business practices related to the company's reporting of discounts to drug distributors [1][2]. Group 1: Legal Issues - The lawsuit concerns whether Regeneron and its officers engaged in securities fraud or other unlawful business practices [2]. - The U.S. Department of Justice filed a complaint against Regeneron under the False Claims Act, alleging the company failed to report millions in discounts, which inflated the Average Sales Price for its products, leading to increased Medicare reimbursements [3]. Group 2: Financial Impact - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36%, closing at $904.70 on April 12, 2024 [4]. - On October 31, 2024, Regeneron reported third quarter 2024 financial results, showing only a 3% increase in U.S. net sales for Eylea HD and Eylea, with Eylea HD sales at $392 million, missing estimates of $415 million to $425 million [5]. - After the financial results were released, Regeneron's stock price dropped by $84.59, or 9.2%, closing at $838.20 on October 31, 2024 [5].

Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN) ...

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN ...

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron as well as certain of ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/regeneron-ph ...

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN ...

Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More ...

Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN ...

Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN ...